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Following its identification as a liver-expressed antimicrobial pep-
tide, the hepcidin peptide was later shown to be a key player in
iron homoeostasis. It is now proposed to be the ‘iron hormone’
which, by interacting with the iron transporter ferroportin,
prevents further iron import into the circulatory system. This con-
clusion was reached using the corresponding synthetic peptide,
emphasizing the functional importance of the mature 25-mer
peptide, but omitting the possible functionality of its maturation.
From urine-purified native hepcidin, we recently demonstrated
that a proportion of the purified hepcidin had formed iron–
hepcidin complexes. This interaction was investigated further by
computer modelling and, based on the sequence similarity of hep-
cidin with metallothionein, a three-dimensional model of hepci-
din, containing one atom of iron, was constructed. To characterize
these complexes further, the interaction with iron was analysed
using different spectroscopic methods. Monoferric hepcidin was
identified by MS, as were possibly other complexes containing
two and three atoms of iron respectively, although these were
present only in minor amounts. UV/visible absorbance and CD
studies identified the iron-binding events which were facilitated
at a physiological pH. EPR spectroscopy identified the ferric state
of the bound metal, and indicated that the iron–hepcidin com-
plex shares some similarities with the rubredoxin iron–sulfur
complex, suggesting the presence of Fe3+ in a tetrahedral sulfur
co-ordination. The potential roles of iron binding for hepcidin
are discussed, and we propose either a regulatory function in the
maturation of pro-hepcidin into active hepcidin or as the necessary
link in the interaction between hepcidin and ferroportin.
Key words: ferroportin, haemochromatosis, hepcidin, iron
homoeostasis, propeptide maturation.
INTRODUCTION
In searching for antimicrobial peptides in the human liver, the 25-
amino-acid protein LEAP-1 (liver-expressed antimicrobial pep-
tide-1), also called hepcidin, was identified in human blood ultra-
filtrate [1] and in urine [2]. Although several bacterial and yeast
species exhibited sensitivity on treatment with the corresponding
synthetic peptide, the results of previous studies proposed a
predominant role for hepcidin in regulating iron homoeostasis
[3]. In mice, expression levels of hepcidin were found to be inver-
sely proportional to the iron content in their food, and over-
expression of hepcidin resulted in iron deficiency anaemia [4].
In humans, hepcidin expression was found to be decreased in
patients with haemochromatosis and is affected by hypoxia and
inflammation, suggesting a key role in iron homoeostasis under
various pathophysiological conditions [5–7]. Hepcidin has now
been shown to bind to the iron exporter ferroportin, leading to a
decreased export of cellular iron into the blood circulation [8].
In identifying such a receptor for hepcidin, its role was defined
as the hormone controlling iron uptake from the intestine and
macrophages.
In humans, the active peptide is derived from the cleavage of
the C-terminus of an 84-amino-acid precursor [2]. A predicted
signal-sequence cleavage site would produce a 60-amino-acid
residue propeptide with an unknown function. Pro-hepcidin was
identified in plasma, and several studies have tried to relate the
level of propeptide to the level of hepcidin, showing, for example,
enhanced levels of pro-hepcidin in patients with chronic renal
insufficiency and a decreased level in patients with hereditary
haemochromatosis and patients with renal anaemia [9]. On the
other hand, Kemna et al. [10] recently demonstrated that the level
of hepcidin is increased during inflammation and decreased in
patients with iron deficiency and thalassaemia major, whereas
serum pro-hepcidin levels displayed no significant difference
between all of the groups tested. A consensus site for the
convertase family of mammalian propeptide-processing enzymes
has been identified at Arg59, and furin, a member of this family of
proprotein convertases which is largely expressed in the liver, has
recently been shown to mediate the post-translational processing
of hepcidin [11]. In cell culture, no pro-hepcidin could be detected
in the medium under control conditions, whereas inhibition of
furin activity resulted in secretion of the propeptide into the
medium, demonstrating the role of furin in cellular maturation
of the active peptide. Although the pro-region of hepcidin is
therefore proposed to facilitate peptide transit through subcellular
compartments and prevent the potentially toxic effect of the
mature cationic peptide, a role for pro-hepcidin in the regulation
of the production of active hepcidin cannot be excluded.
Apart from its proposed interaction with ferroportin, the
mechanism of hepcidin as an iron sensor still needs to be
investigated. As a result of the low physiological concentration
of hepcidin, together with the difficulties encountered in its
purification, most of the work on hepcidin has been carried out
using the corresponding synthetic peptide. In order to investigate
the direct interaction of the peptide with iron, as observed for
most of the proteins involved in iron metabolism, we analysed a
small amount of the peptide isolated from urine [12]. Iron was
found to be bound to a proportion of the purified peptide, which
led us to build a three-dimensional model of iron-bound hepcidin
[12]. This model, which is based on sequence similarities with
the metallothionein protein family, is different from the solved
structure of the synthetic peptide, but corresponds to the only
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published CD spectrum of the native peptide [2]. In the present
study, the direct interaction of iron with hepcidin is investigated
further by biophysical characterization of the iron-containing
hepcidin complex.
MATERIALS AND METHODS
Peptide
The oxidized synthetic 25-mer hepcidin, purified to >95% by
HPLC, was purchased from Alpha Diagnostic (San Antonio, TX,
U.S.A.) with its cysteine residues air-oxidized. The oxidized
peptide was resuspended (final concentration of 0.5 mg/ml) in
10 mM Hepes (pH 7.5) and 100 mM NaCl. To reduce the peptide,
TCEP [tris-(2-carboxyethyl)phosphine] · HCl was added to the
solution at a final concentration of 2.5 mM. Iron was added from
a stock solution of Fe3+ HCl (ferric iron solution; 0.54 mM).
MS analysis
Data were obtained using a Waters Micromass MS Technologies
MALDI (matrix-assisted laser-desorption ionization) micro
MXTM mass spectrometer operating with a positive polarity in
a linear mode. α-Cyano-4-hydroxcinnamic acid was used as the
sample matrix.
EPR analysis
Samples were frozen in quartz tubes (3 mm internal diameter) at
12 K; microwave power, 20 mW; frequency, 9.379 GHz; magnetic
field modulation amplitude, 1 mT; and frequency, 100 kHz.
Absorption and CD analysis
All spectra were acquired using the Applied Photophysics
Chirascan spectropolarimeter, and 10 mm and 0.5 mm Suprasil
rectangular cells were employed. Measurements were performed
with a stepsize of 0.5 nm and time-per-point of 1.5 s in the visible
and near-UV (750–230 nm) regions and 3.0 s in the far-UV (260–
190 nm) region. The instrument was flushed continuously with
pure evaporated nitrogen throughout the experiment. All CD and
UV spectra were buffer-baseline corrected.
RESULTS
In order to mimic an intracellular interaction between iron and the
peptide under the conditions which would be encountered initially
following peptide translation in the ER (endoplasmic reticulum),
the reduced form of the peptide was chosen to be assessed for
iron binding. However, on resuspension of the synthetic freeze-
dried reduced peptide, the peptide was found to be partially
insoluble. It was therefore decided to use the oxidized form of
the synthetic peptide resuspended in the same dilution buffer, but
without a reducing agent, and to proceed with its reduction after
resuspension.
MS analysis
After confirming the oxidized state of the synthetic 25-mer pep-
tide (0.18 mM) by MS analysis (results not shown), the peptide
was then reduced using TCEP at a final concentration of 2.5 mM.
After 30 min of incubation, complete reduction of the peptide
was confirmed by MS analysis by the presence of a peak at
2797 Da (results not shown). It is noteworthy that, although
direct solubilization of the freeze-dried reduced peptide was
not successful, the peptide resulting from the reduction of the
Figure 1 MS spectra of hepcidin peptide incubated with iron
After addition of iron to the reduced peptide, a peak at 2853 Da, corresponding to the mass
of iron-bound hepcidin, was detected. The y-axes show the percentage intensity in relation
to the highest peak shown. The predicted distribution of the relative isotopic abundance (A)
corresponds to the distribution obtained in the experimental spectrum (B). The value at the top
of each peak is the mass of the peak in Da.
solubilized oxidized peptide was perfectly soluble. Iron was added
to the newly reduced peptide successively in three batches of Fe3+
HCl to a final concentration of 0.54 mM. MS analysis of the
mixture indicated that a proportion of the peptide was found to
be iron-bound, with a peak at 2853 Da (Figure 1). The validity of
the results was confirmed by the corresponding distribution of the
relative isotopic abundance between the obtained and predicted
profiles (Figure 1). The molecular mass also indicates that iron
binding to the peptide does not result in deprotonation and sug-
gests a chelate complex, as observed with other metal complexes
[13] such as rubredoxin [14] and ferredoxin I [15]. Although
the largest proportion of the iron-containing complex identified
corresponds to the molecular mass of a monoferric iron–hepcidin
complex, other species of molecular mass, corresponding to iron–
hepcidin with two and three atoms of iron bound per peptide, were
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 2 CD spectra of hepcidin in the presence and absence of iron
(A) In the far-UV region, no changes can be observed in CD after the addition of TCEP and
reduction of the peptide, and only a minor increase can be measured after addition of iron.
(B) The CD spectrum of reduced hepcidin alone has been subtracted from the CD spectrum of
reduced hepcidin with added iron; the prominent negative peak in the visible region at 650 nm
confirms that iron is bound to the peptide.
also obtained in minor amounts (results not shown), suggesting
the existence of several forms of iron–hepcidin.
UV absorption and CD spectroscopy
UV absorption and CD spectroscopy were used to investigate
further the ability of the peptide to bind iron by comparing the
spectra obtained with the different peptides before and after
the addition of iron. When absorbance in the near-UV region was
compared between the oxidized and reduced peptides, no major
changes were observed; only a slight decrease around 275 nm,
which probably relates to the reduction of the four disulfide
bridges (results not shown). The CD spectrum of the oxidized
peptide before the addition of iron did not possess any positive
ellipticity in the far-UV region, suggesting the peptide possessed a
disorganized structure, similar to the original spectrum published
previously for the native peptide [2], but with a different secondary
structure content from that described for the synthetic peptide
[16]. In order to detect any changes in conformation following
reduction of the peptide, CD spectra were measured after the addi-
tion of TCEP. No changes were observed, indicating that the
reducing agent had no effect on the peptide secondary structure
(Figure 2). Following each successive addition of Fe3+ HCl to the
reduced peptide, a slight increase in absorbance was observed at
approx. 280 nm, which is typical of a charge-transfer transition
between the metal and the peptide following the binding of iron
(results not shown). The same event was followed by measuring
its CD. In the far-UV region, only a small increase in CD was
observed after the addition of iron (Figure 2A). In the near-UV
region, the presence of two distinct positive peaks at approx. 250
and 300 nm, and a more prominent negative peak in the visible
region at 650 nm, all confirm that iron was bound to the peptide
(Figure 2B). Following the addition of different components to the
mixture, variations in the pH of the solution had to be considered
as a result of the lowering effect of TCEP on the pH, since the
addition of Fe3+ HCl to the solution was calculated to lower the pH
of the solution to approx. pH 3. In order to re-establish conditions
closer to physiological conditions, the pH was increased to 7.2 by
adding crystals of Trizma base to the solution. The pH increase
had an immediate effect, with a drastic amplification of all of the
variations described above following the addition of iron (results
not shown).
EPR spectroscopy
In order to identify the nature of the iron complex, the reduced
peptide solution containing iron was subjected to EPR analysis.
The observation of the spectrum indicated that iron was in its
ferric state, with a g-factor value of approx. 4.3 (Figure 3). Such
a prominent absorption derivative near g = 4.3 is typical of high-
spin Fe3+ in a centre of rhombic symmetry, and arises from the
S =+− 3/2 Kramers doublet of the S = 5/2 ion. This is found in non-
haem iron proteins such as transferrin, ferrichrome or rubredoxin,
which have single iron centres [17]. In the small bacterial iron–
sulfur protein rubredoxin, the tetrahedral iron centre is chelated by
four cysteine residues (Figure 3) [18]. Additional signals may be
observed at g = 9, corresponding to the S =+− 1/2 and S =+− 5/2
Kramers doublets [19], but these are expected to be of lower
amplitude; a broad feature was detected in this region, which may
represent broadening due to strain effects.
DISCUSSION
Hepcidin has been shown to play an important role in the
regulation of iron homoeostasis [20]. After binding to the iron
transporter ferroportin, hepcidin facilitates its endocytosis, hence
preventing iron distribution from the intestine and macrophages
within the body [8]. The majority of this work has been performed
using the corresponding synthetic peptide, therefore demonstrat-
ing the importance of the primary structure in its function, but
omitting other structural properties that could have functional
importance in its regulation. In order to study the structural and
functional relevance of its native state, a pilot study was carried
out using urine-purified native hepcidin where we reported the
isolation of iron-bound hepcidin [12]. Following such findings,
iron binding to hepcidin was investigated further using the
synthetic corresponding peptide, and the results are reported in
the present study.
In order to mimic an iron-binding event that would occur during
maturation of the peptide, the reduced form of hepcidin was
chosen for use in binding assays. However, since the freeze-dried
synthetic reduced peptide was found to be partially insoluble,
the oxidized form was therefore used as starting material and
was reduced after solubilization. The CD profile obtained for the
solubilized oxidized peptide was similar to the only published
spectra of native hepcidin [2], with both spectra being character-
istic of a peptide with no organized secondary structure [21];
in contrast with the published structure of the synthetic peptide,
which showed a distorted β-sheet structure [16]. The reduction
of the four disulfide bridges did not have a major effect on the
secondary structure of the peptide, since the spectra were compar-
able, but it allowed the binding of iron following the addition of
Fe3+ HCl, as indicated by MS detection of the components, with
masses corresponding to ferric–hepcidin complexes. Although
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 3 EPR spectra of iron-bound hepcidin
The signal at g = 4.3, which is present in the iron/hepcidin solution (A) and is absent in the iron-only solution (B), is characteristic of a rubredoxin-type signal, with Fe3+ in tetrahedral sulfur
co-ordination as illustrated above the spectra.
the highest proportion of iron-containing hepcidin complexes
identified were monoferric, complexes of masses corresponding
to diferric and triferric complexes were also identified, but in
minor amounts. The increase in absorbance observed following
the increase in pH indicates a stronger affinity for iron at neutral
pH, which could relate to a weaker protonation of the cysteine
residues. Although the partial precipitation of ferric iron at higher
pH values cannot be ignored and could also be responsible to some
degree for the change in absorbance, the differences observed in
the CD profiles in the visible region after the addition of iron
confirmed iron binding to the peptide. The binding of iron to the
peptide was further substantiated by EPR analysis, where
the presence of a spectrum implies the detection of iron in the
ferric state. In addition, the shape of the spectrum characteristic of
rubredoxin, a small protein found in various sulfur-metabolizing
bacteria, strongly suggests an iron–sulfur complex involving one
atom of iron chelated by four cysteine residues. Rubredoxin
is a small protein, containing one atom of iron bound to the
sulfur atoms of four cysteine residues, forming an iron–sulfur
complex with tetrahedral symmetry, which has been proposed
to be involved in electron transfer [22]. A redox function for
hepcidin has never been suggested, but a role for the peptide in the
oxidation of ferrous to ferric iron could relate to its interaction with
the ferrous iron transporter ferroportin, although such a function
would have to be clarified. The question of the role of iron binding
to hepcidin therefore remains unresolved.
The demonstrated activity of injected iron-free synthetic
hepcidin [23] implies that iron could only participate directly in
the peptide interaction with ferroportin if its binding to hepcidin
occurred prior to or through its interaction with ferroportin.
Although iron binding to the oxidized synthetic peptide could not
be achieved in vitro (results not shown), the nature of the chelate
complex suggests that the reduction of the four disulfide bridges
might not be necessary under physiological conditions to allow
iron to bind to the peptide. In addition, since the presence of
free iron is quite unlikely, its interaction with hepcidin could
involve a carrier, for which ferroportin would be a prime
candidate. Therefore an interaction of iron with the oxidized
mature peptide at a later stage and following its secretion cannot
be excluded but remains to be demonstrated.
A role for iron binding, distinct from the function of hepcidin
as a ligand for ferroportin, might be found in the regulation
of hepcidin peptide maturation. Although the present study has
been carried out using the synthetic peptide equivalent to the 25-
mer hepcidin, iron binding might be considered not only with
regards to the active peptide, but also its precursor pro-hepcidin.
Apart from the eight cysteine residues present in the 25-mer
corresponding to the active peptide, the pro-hepcidin sequence
does not contain any other cysteine residues, so it is therefore
reasonable to assume that the described iron–sulfur cluster would
not be compromised. In the model of iron binding inside the
cell, binding of iron could play a role in regulating maturation
of the propeptide, a model based on existing mechanisms such as
the ‘cysteine switch’ activation mechanism of the MMP (matrix
metalloproteinase) family, where the mechanism relies on un-
masking of the cleavage site following metal binding to a
cysteine residue on the protease [24]. A similar mechanism could
be involved in the maturation of pro-hepcidin into hepcidin;
although, in contrast with MMPs, it is the binding of iron,
and not its dissociation, that would allow the unmasking of the
RRRRD cleavage site. Such a mechanism would depend on
the local iron content, as at low iron concentrations the cleavage
site of the folded iron-free propeptide would be inaccessible to the
convertase, whereas at high iron concentrations, iron binding to
the propeptide would engender sufficient conformational changes
to permit access to the cleavage site and lead to maturation of
the propeptide into the active peptide, followed by its secretion
(Figure 4).
To conclude, we propose two hypotheses for the role of iron
binding to hepcidin that both imply another direct role of iron in
the regulation of its absorption. In the first instance, iron could
be directly involved in the interaction between hepcidin and
ferroportin, with a selective interaction of hepcidin and only ferro-
portin actively transporting iron, which would explain the
different effects of hepcidin observed between enterocytes and
macrophages [25]. In the second mechanism, following binding
of iron, the conformational changes sustained by pro-hepcidin
would lead to the unmasking of the cleavage site and therefore to
its accessibility to the convertase furin, leading to maturation of
the active 25-mer peptide. Such a mechanism of regulation at the
c© The Authors Journal compilation c© 2008 Biochemical Society
Iron-bound hepcidin complex 557
Figure 4 Hypothetical mechanism of maturation of hepcidin
In the absence of ligand, the cleavage site is masked by the pro-domain; but in the presence
of ligand, displacement of the pro-domain following a conformational change as a result of the
binding of a ligand, i.e Fe or NO, to the cysteine residues allows the convertase to access
the cleavage site, leading to the maturation of pro-hepcidin into the active 25-mer hepcidin.
post-translational level is not a substitute for the more complex
mechanism of regulation described at the transcriptional level,
but is simply a complementary mechanism of a first response to
subtle variations in iron levels in the cell, as observed with other
hormone mechanisms.
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